These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 19446594)

  • 1. Cost-effectiveness of infant vaccination with RIX4414 (Rotarix) in the UK.
    Martin A; Batty A; Roberts JA; Standaert B
    Vaccine; 2009 Jul; 27(33):4520-8. PubMed ID: 19446594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France.
    Standaert B; Parez N; Tehard B; Colin X; Detournay B
    Appl Health Econ Health Policy; 2008; 6(4):199-216. PubMed ID: 19382820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination.
    Jit M; Edmunds WJ
    Vaccine; 2007 May; 25(20):3971-9. PubMed ID: 17400341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of childhood rotavirus vaccination in Germany.
    Aidelsburger P; Grabein K; Böhm K; Dietl M; Wasem J; Koch J; Ultsch B; Weidemann F; Wichmann O
    Vaccine; 2014 Apr; 32(17):1964-74. PubMed ID: 24561052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness evaluation of a rotavirus vaccination program in Argentina.
    Martí SG; Alcaraz A; Valanzasca P; McMullen M; Standaert B; Garay U; Lepetic A; Gomez J
    Vaccine; 2015 Oct; 33(42):5684-5690. PubMed ID: 26303875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands.
    Goossens LM; Standaert B; Hartwig N; Hövels AM; Al MJ
    Vaccine; 2008 Feb; 26(8):1118-27. PubMed ID: 18215445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential epidemiological and economical impact of two rotavirus vaccines in Colombia.
    De la Hoz F; Alvis N; Narváez J; Cediel N; Gamboa O; Velandia M
    Vaccine; 2010 May; 28(22):3856-64. PubMed ID: 20347057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of rotavirus vaccination in China: Projected possibility of scale-up from the current domestic option.
    Cui S; Tobe RG; Mo X; Liu X; Xu L; Li S
    BMC Infect Dis; 2016 Nov; 16(1):677. PubMed ID: 27846803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of rotavirus vaccination in Armenia.
    Jit M; Yuzbashyan R; Sahakyan G; Avagyan T; Mosina L
    Vaccine; 2011 Nov; 29(48):9104-11. PubMed ID: 21945959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of a pentavalent human-bovine reassortant rotavirus vaccine for children ≤5 years of age in Taiwan.
    Itzler RF; Chen PY; Lac C; El Khoury AC; Cook JR
    J Med Econ; 2011; 14(6):748-58. PubMed ID: 21919673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe.
    Jit M; Bilcke J; Mangen MJ; Salo H; Melliez H; Edmunds WJ; Yazdan Y; Beutels P
    Vaccine; 2009 Oct; 27(44):6121-8. PubMed ID: 19715781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland.
    Tilson L; Jit M; Schmitz S; Walsh C; Garvey P; McKeown P; Barry M
    Vaccine; 2011 Oct; 29(43):7463-73. PubMed ID: 21821085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Rotavirus vaccination in Vietnam.
    Kim SY; Goldie SJ; Salomon JA
    BMC Public Health; 2009 Jan; 9():29. PubMed ID: 19159483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of a pentavalent rotavirus vaccine in Japan.
    Itzler R; O'Brien MA; Yamabe K; Abe M; Dhankhar P
    J Med Econ; 2013 Oct; 16(10):1216-27. PubMed ID: 23919721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
    Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
    Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of rotavirus vaccination in Argentina.
    Urueña A; Pippo T; Betelu MS; Virgilio F; Hernández L; Giglio N; Gentile Á; Diosque M; Vizzotti C
    Vaccine; 2015 May; 33 Suppl 1():A126-34. PubMed ID: 25919152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential impact and cost-effectiveness analysis of rotavirus vaccination of children in Israel.
    Chodick G; Waisbourd-Zinman O; Shalev V; Kokia E; Rabinovich M; Ashkenazi S
    Eur J Public Health; 2009 Jun; 19(3):254-9. PubMed ID: 19221026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Budget impact and cost-utility analysis of universal infant rotavirus vaccination in Spain.
    Imaz I; Rubio B; Cornejo AM; González-Enríquez J
    Prev Med; 2014 Apr; 61():116-21. PubMed ID: 24360847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and "no medical care'' disease impact in Belgium.
    Bilcke J; Van Damme P; Beutels P
    Med Decis Making; 2009; 29(1):33-50. PubMed ID: 18948433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of a pentavalent rotavirus vaccine in Oman.
    Al Awaidy ST; Gebremeskel BG; Al Obeidani I; Al Baqlani S; Haddadin W; O'Brien MA
    BMC Infect Dis; 2014 Jun; 14():334. PubMed ID: 24941946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.